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Objectives:  There  is  evidence  that  menopausal  symptoms  manifested  at peri-menopause  occur  less  fre-
quently when  compared  to  the  symptoms  experienced  at post-menopause.  The aim  of  this  study  was
to investigate  this  and  to test the hypothesis  that  depressive  symptomatology  mediates  the  relationship
between  menopausal  stage  and  symptom  frequency.
Methods: This  cross-sectional  study  included  213  women  (M  age  =  52  years),  of  whom  125 were peri-
and  88  post-menopausal.  Measures  comprised  the Center  for Epidemiologic  Studies-Depression  scale
(CES-D)  and  the  Women’s  Health  Questionnaire  (WHQ)  vasomotor  symptoms  and  somatic  symptoms
subscales.
Results:  Multiple  mediated  regression  analyses  provided  evidence  that  somatic  symptoms  and  vasomotor
symptoms  were  less  frequent  at post-  compared  to peri-menopause,  and  that  these  differences  were
mediated  by depressive  symptomatology.  Multivariate  effect  sizes  ranged  from small  to moderate,  and
univariate  effect  sizes  were  uniformly  small  with  wide  conﬁdence  intervals.
Conclusions:  The  frequency  of vasomotor  and  somatic  symptoms  appears  to increase  with depressed
affect.  The  management  of symptoms  could  include  interventions  of  a psychotherapeutic  nature,  which
may  offset  this effect,  particularly  in  women  for whom  depressive  symptoms  are a  feature  of  the  climac-
teric  syndrome.  The  extent  to  which  depression  and  the  climacteric  syndrome  may  be causally  related  to
one another  remains  unclear  and  longitudinal  research  should  further  examine  the  mechanisms  of  this
association.
rs.  Pu© 2015  The  Autho
. Introduction
Depression is the single greatest cause of disability world-
ide and women are almost twice as likely as men  to suffer
ajor depressive disorders (odds ratio 1.7, 95% conﬁdence interval
.5–2.0) [1,2]. A possible explanation for the gender difference in
ulnerability for depression between men  and women are varying
evels of the gonadal hormones estrogen and progesterone [3–5].
eproductive cycle events, like the menopausal transition, have
lso been implicated as windows of vulnerability for depression in
omen [6]. During menopause women are more likely to expe-
ience somatic/physical (e.g., insomnia, headaches, paresthesia)
∗ Corresponding author. Tel.: +44 1202 966671.
E-mail addresses: Erika.borkoles@vu.edu.au (E. Borkoles),
ick.Reynolds@acu.edu.au (N. Reynolds), David.Thompson@acu.edu.au
D.R. Thompson), Chantal.Ski@acu.edu.au (C.F. Ski), Lily.Stojanovska@vu.edu.au
L. Stojanovska), rpolman@bournemouth.ac.uk (R.C.J. Polman).
ttp://dx.doi.org/10.1016/j.maturitas.2015.03.007
378-5122/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/4.0/).blished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and vasomotor (e.g., hot ﬂashes, night sweats) symptoms caused
by serotonergic and non-adrenergic ﬂuctuations [7]. In particular
vasomotor symptoms (VSM) have been associated with depressive
symptoms (domino hypothesis [8]). Together with psychosocial
and behavioural factors (e.g., social support, loss of interest in
sex, stressful events) women  transitioning into menopause might
be particularly susceptible to mood disturbances in general and
depressive symptomology in particular.
Mood disturbances are reported by 75% of peri-menopausal
women [9] and are routinely assessed in surveys examin-
ing menopausal symptomology (e.g., depression, anxiety and
irritability). There is currently no consensus whether depression
or depressive symptoms constitute core menopausal symptoms
[10]. Some researchers have excluded depression from the diagnos-
tic criteria for reproductive related disorder [11], whereas others
have shown in longitudinal studies that in particular the peri-
menopausal period is associated with a changing hormonal milieu
and increased occurrence (up to 2 to 14 fold) of depressive symp-
tomology compared to pre-menopause [12–14].
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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Table 1
Demographic characteristics (n = 223).
Variables n (%)
Ethnicity
Anglo-Celtic 157 (70.2)
European 42 (18.8)
Asian 12 (5.0)
Other 12 (5.0)
Education level
Secondary 31 (14.0)
Trade or diploma 45 (20.3)
University degree 67 (30.1)
Post-graduate degree 79 (35.6)
Employment status
Full time 105 (70.5)
Part time 32 (21.5)
Not  in paid employment 12 (8.0)
Parity
Nil  52 (23.3)
One 28 (12.6)
Two 94 (42.2)
≥Three 49 (22.0)
Relationship status
Married 96 (64.0)
Separated or divorced 29 (19.4)
Single 24 (16.1)E. Borkoles et al. / Ma
The equivocal ﬁndings with regard to depressive episodes in
enopause are partly due to methodological (e.g., epidemiolog-
cal vs. clinical studies), diagnostic (assessment of depression;
elf-report vs. clinical assessment), and menopausal status differ-
nces [15]. For example, epidemiological studies have generally
ound no increase in depressive symptoms in menopause, whereas
linical studies have found higher prevalence rates [16]. In
ddition, differences exist in regard to menopausal symptom
everity during the peri- vs. post-menopausal periods [17]. More
ecently, Freeman et al. [18] identiﬁed higher risk of depres-
ive symptoms leading up to the ﬁnal menopausal period and
ower risk thereafter. However, for women with a history of
epression the risk signiﬁcantly increased both before and after
enopause.
A number of risk factors have been identiﬁed, which might result
n menopausal women experiencing more or less depression or
epressive symptoms. These include VMS  [19], hormonal vulnera-
ility [20], socioeconomic status (SES), education and achievement
higher SES, education and income resulting in less depressive
ymptoms), smoking, exercise, body mass index (BMI), social sup-
ort and partner status, coping, attitude, stressful life events and
ast history of mood disorder [21].
Elucidation of the role of depression during different stages of
enopause (peri- vs. post) is of clinical relevance given its seri-
us consequences for health and cognition. Menopausal symptoms
ncluding depression greatly inﬂuences well-being and quality of
ife [22]. In addition, depression is associated with other chronic
iseases including metabolic syndrome, osteoporosis, cardiovascu-
ar disease [18] and reduced cognitive functioning [23]. Therefore,
he present study examined whether depressive symptomatology
ediates the hypothesized association between menopausal status
nd menopausal symptoms.
. Methods
.1. Participants
The study included 213 participants (M age = 52.2 years,
D = 5.9) of which 125 were classiﬁed as peri-menopausal (58%;
 age = 50 years, SD = 4.2) and 88 post-menopausal (42%; M
ge = 54.2 years, SD = 5.9). The sample included 17 participants
ho had undergone a surgical procedure that might affect their
xperience of menopause. Two post-menopausal women had
ach undergone a hysterectomy with bilateral oophorectomy, and
5 peri-menopausal participants had undergone a hysterectomy
n = 8) or hysterectomy with unilateral oophorectomy (n = 7). The
ample contained no reports of chronic and debilitating illness and
o psychoactive substance use was reported. Over 70% of partici-
ants were of Anglo-Celtic origin, most were employed on a full-
r part-time basis, possessed a tertiary qualiﬁcation, and had one
r more children (see Table 1). Ethical approval for the study was
rovided by Victoria University Human Research and Ethics Com-
ittee.
.2. Procedure
A cross-sectional study of menopause and depressive symp-
oms was undertaken with female volunteers recruited at
eri-menopause (deﬁned as the period from the commence-
ent of menstrual irregularity to one year after the cessation
f menstrual periods) and post-menopause (deﬁned as one year
r more after the cessation of menstrual periods) [24]. Par-
icipants were recruited via advertisements displayed in print
edia of the Queensland Menopause Society, advertisements
isplayed on the website of the Australian Menopause Society,Current smoker 25 (11.2)
and leaﬂets distributed at support organisation (e.g. Women’s
Wellness West). Consenting participants provided demographic
information, including age, income, paid employment, parity and
cigarette smoking and completed a questionnaire pack containing
measures of depressive symptomatology and menopausal symp-
toms. Hard-copy and digital forms of the questionnaire pack were
accessed via web-link and required between 25 and 30 min  to com-
plete.
2.3. Materials
2.3.1. The Center for Epidemiologic Studies of Depression Scale
(CES-D)
This widely-used 20-item CES-D [25] questionnaire asks par-
ticipants to indicate the frequency of depressive symptoms
experienced during the preceding week. Participants respond to
items using a 4 point Likert scale, which ranges from 0 (“rarely or
none of the time”) to 3 (“most or all the time”). The CES-D yields a
total score, which ranges from 0 to 60. Participants who score ≥16
are considered likely to be at risk of depression [25,41]. The internal
consistency of the CES-D for the present sample was  high (  ˛ = 0.92)
and comparable to that obtained from previous samples [26].
2.3.2. The Women’s Health Questionnaire (WHQ)
This 36-item WHQ  questionnaire [27] assesses the frequency of
menopausal symptoms over the preceding few days. Participants
respond using ﬁve point scale with a range from 1 (“Yes, deﬁnitely”)
to 5 (“No, not at all”). The subscales of the WHQ  comprise self-
perceived attractiveness, depression, anxiety, sleep disturbance,
sexual dysfunction, menstrual symptoms, VMS  and somatic symp-
toms. Responses to items within each subscale are summed and
re-scaled to range from 0 to 1, with higher scores corresponding
to greater symptom frequency. The reliability of the vasomotor
symptoms subscale (  ˛ = 0.83) and the somatic symptoms subscale
(˛ = 0.79) ranged from adequate to good in the present sample.
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.4. Analysis strategy
The data were analysed with IBM Statistical Package for the
ocial Sciences (SPSS) version 22 and PROCESS [28]. A preliminary
nalysis used odds ratios to test differences in symptom prevalence
s a function of menopausal status and CES-D high- and low depres-
ion risk categories. The outcome variables were dichotomized
uch that 0 denoted symptom absent and 1 denoted symptom
resent.
Mediated multiple regression models were constructed to pre-
ict symptom frequency as a direct function of menopausal status
nd symptom frequency as an indirect function of menopausal
tatus through depression, controlling for income, smoking sta-
us, and parity. The indirect effect was estimated with bootstrap
ias-corrected and accelerated (BCa) conﬁdence intervals that were
enerated from 5000 samples [29].
Bootstrap BCa CI point estimates are reported and unstandard-
zed regression coefﬁcients for path a [X (menopausal status) to M
depression)], controlling for covariates income, parity, smoking),
ath b [M to Y (vasomotor or somatic symptoms)] controlling for X),
nd path c′ (X to Y controlling for M and covariates). In addition, two
ndices of explained variance are reported. The coefﬁcient of deter-
ination (R2) and Kappa-squared (K2), which is the indirect effect
xpressed as a proportion of the maximum possible indirect effect
ased on the variances of X, M,  and Y and their inter-correlations
30].
The product of coefﬁcients method was used to estimate the
ample size required for 80% power to detect an indirect effect (ab)
nd assumed medium sized effects at paths a and b. A sample of
1 participants provided sufﬁcient power using the bootstrap bias-
orrected method at  ˛ of 0.05 [31].
. Results
A square root transformation of the CES-D normalized its error
istribution and brought several outlying values within a more
robable range of the distribution’s mean. Missing values, 3% of
ases, were regarded as missing at random and excluded from the
nalyses. There were otherwise no substantive violations of the
ultivariate assumptions.
.1. Symptom prevalence
Sixteen percent of participants who reported no somatic symp-
oms, while 36% reported no VMS. There was a higher likelihood of
xperiencing VMS  given peri-menopausal status (OR: 1.95; [95%
I: 1.11 to 3.39], p < 0.001), whereas the prevalence of somatic
ymptoms did not signiﬁcantly differ between menopausal groups.
revalence was positively correlated with CES-D depression risk
ategories. Participants in the high risk group were more likely
o experience VMS  (OR: 3.01; [95% CI: 1.68 to 5.36]) and somatic
ymptoms (OR: 14.58; [95% CI: 3.36 to 63.27]) relative to partic-
pants who scored 15 or less on the CES-D. Table 2 displays the
eans and standard deviations of VMS  and somatic symptoms
ccording to menopausal and depressive symptomology status.
.2. The frequency of VMS
The parameters of the mediation analyses are shown in Table 3a.
he multiple regression model with covariates explained 11% of the
ariance in VMS  scores as a function of depression and menopausal
tatus (R2 = 0.11 [95% CI: 0.03 to 0.18]). The effect sizes of path a
Cohen’s d = 0.30) and path b (2 = 0.04) were small according to
onventional guidelines. There were fewer symptoms of depressed
ffect at post- than peri-menopause (a = −0.41 [95% CI: −0.87
o −0.08]) and participants with elevated depressive symptomss 81 (2015) 306–310
tended to report more frequent VMS  (b = 0.06 [95% CI: 0.01 to 0.10])
holding the covariates constant at both paths and controlling for the
effect of menopausal status at path b.
There was  a direct effect of menopausal status on VMS  (c′ = −0.15
[95% CI: −0.30 to −0.05]). The BCa CI of the indirect effect excluded
zero and the point estimate indicated a reduction in the fre-
quency of VMS  through depression (ab = −0.023 [95% CI: −0.063 to
−0.002]). The indirect effect explained 3% of the maximum possible
indirect effect based on the model without covariates (K2 = 0.033;
SE = 0.01 [95% CI: 0.006 to 0.075]).
3.3. The frequency of somatic symptoms
The multiple regression model with covariates explained 27% of
variance in somatic symptom scores as a function of the antecedent
and mediator variables (R2 = 0.27 [95% CI: 0.16 to 0.37]) (Table 3b).
The effect size at path b was large (2 = 0.24) and the unstan-
dardized coefﬁcient indicated that somatic symptoms increased
with depressive symptoms (b = 0.08 [95% CI: 0.06 to 0.10]) control-
ling for the covariates and menopausal status. The BCa CI of the
indirect effect excluded zero and indicated fewer somatic symp-
toms at post- relative to peri-menopause through depression scores
(ab = −0.03; SE = 0.01 [95% CI: 0.069 to 0.005]). The indirect effect
explained 8% of the maximum possible effect based on the proposed
model without covariates (k2: 0.08 [95% CI: 0.01 to 0.15]).
4. Discussion
Menopausal symptoms may  vary from peri- to post-menopause
transition as an indirect function of depressive symptomatology
and the present ﬁndings provide support for this hypothesis. From
peri- to post-menopause, depressed affect mediated a decline in
the frequency of VMS  and somatic symptoms, controlling for the
effects of income, parity, and tobacco use.
The prevalence of VMS  and somatic symptoms in the present
sample was not dissimilar to that obtained in other women in
Western cultures [13,27]. In addition, our ﬁndings support the
notion that peri-menopausal women  experience a higher fre-
quency of symptoms than post-menopausal women. In particular,
VMS prevalence is higher in the years before the ﬁnal menstrual
period (FMP) and peaks at approximately 1 year after [32].
Our study found a difference of one unit on the WHQ  response
scale from peri- to post-menopause, which reﬂects a substantive
or ‘clinically signiﬁcant’ degree of change [33]. Part of this over-
all effect was directly attributable to menopausal status and a
portion was due to the mediator depression (partial mediation).
In particular, menopausal status predicted fewer depressive symp-
toms among postmenopausal participants, which corresponded
to reports of less frequent VMS  in this group. The ﬁndings are
broadly compatible with neuro-cognitive theories which attribute
symptom change to the machinations of biological, behavioural,
or psychological entities [34]. There is some evidence that the fre-
quency of hot ﬂushes and night sweats peak at peri-menopause
and then declines in concert with hormonal changes during this
period [35]. The changing hormonal milieu may  also affect depres-
sive symptomatology thereby reducing the frequency of vasomotor
symptoms [36].
The ﬁndings are also compatible with behavioural explanations,
particularly as they pertain to complex patterns of overt behaviour.
For example, there is evidence that VMS  do not decline but instead
are under-reported at post-menopause. This may indicate that
women grow more tolerant of symptoms or become increasingly
proﬁcient at managing their effects during this period. It is conceiv-
able that the indirect effect signiﬁes an increased capacity to cope
E. Borkoles et al. / Maturitas 81 (2015) 306–310 309
Table  2
Symptom frequency according to menopausal status and CES-D risk category (mean (±SD)).
Menopausal status Depressive symptomatology
Peri Post CES-D < 15 CES-D ≥ 16
Vasomotor symptoms 0.61 (0.45) 0.44 (0.44) 0.49 (0.46) 0.65 (0.42)
Somatic  symptoms 0.40 (0.28) 0.38 (0.27) 0.34 (0.26) 0.50 (0.26)
Table 3a
Regression pathways of the mediation model of vasomotor symptom frequency with covariates at paths a and c′ .
Antecedent Depressive symptomatology (M) Vasomotor symptoms (Y)
B SE 95% CI p B SE 95% CI p
Menopausal status (X) a −0.48 0.2 −0.87 to −0.08 0.01 c′ −0.13 0.06 −0.26 to −0.01 0.03
M  – – – – b 0.06 0.02 0.01 to 0.10 0.01
C1 (parity) −0.10 0.08 0.220 −0.01 0.02 0.59
C2 (income) −0.17 0.03 <0.000 −0.02 0.01 0.04
C3 (smoke) −0.72 0.32 0.020 0.00 0.09 0.99
Constant 6.42 0.70 <0.000 0.61 0.26 0.01
R2 = 0.136 R2 = 0.104
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CF(4, 199) = 7.83, p < 0.0001 
: covariate. B: unstandardized regression coefﬁcient. SE: standard error. CI: conﬁd
t post-menopause on average, which manifests in fewer or less
othersome VMS.
There was  no support that somatic symptoms differed as a
unction of menopausal status either before or after controlling
or the indirect effect of depression. However, menopausal sta-
us predicted fewer somatic symptoms at post-menopause through
epression.
The major strength of this study is the clariﬁcation that lead-
ng up to menopausal transition women are much more likely to
e at risk of having depressive symptoms than those who  reached
he FMP, and those with a previous history of depression hav-
ng even greater risk. In addition, peri-menopause is also a time
hen the frequency of some menopausal symptoms may  peak. The
resent study postulated that menopausal status and menopausal
ymptoms are causally related via depression. The mediated regres-
ion analyses of these observational data were consistent with
his notion. Depressive symptoms were less frequent at post-
enopause and this reduction was correlated with fewer reported
asomotor and somatic symptoms.
However, it is still unclear what is the association between
epressive and vaso-motor symptoms and whether it is due to a
ommon physiological mechanisms or not and what their psycho-
ogical and social impact are on women. Freeman et al. [37] found
hat greater variability in FSH (follicle-stimulating hormone) and
stradiol was signiﬁcantly associated with depressive symptoms in
he menopause transition. Those with a faster rate of change in FSH
efore the FMP  had lower risk of depressive symptomology than
hose with or without history of depression after the FMP. Strauss
38] examined possible underlying mechanisms in 986 women
ver a 9-year follow-up. She found that initial levels of depressive
able 3b
egression pathways of the mediation model of somatic symptom frequency with covari
Antecedent Depressive symptomatology (M)  
B SE 95% CI 
Menopausal status (X) a −0.48 0.2 −0.87 to −0.08 
M  
C1 (parity) −0.10 0.08 
C2 (income) −0.17 0.03 
C3 (smoke) −0.72 0.32 
Constant 0.27 0.14 
R2 = 0.136 
F(4,  199) = 7.83, p < 0.0001 
: covariate. B: unstandardized regression coefﬁcient. SE: standard error. CI: conﬁdence iF(5, 198) = 4.62, p < 0.0005
ntervals.
symptoms predicted future menopausal symptoms, and vice versa,
initial levels of menopausal symptoms also predicted depressive
symptoms. This suggests that more than one mechanism inﬂuences
the relationship between menopausal symptoms and depression.
Our results are clinically important, because depression is
strongly associated with poorer quality of life and health limiting
conditions, such as cardiovascular disease. It is a standard practice
for many healthcare professionals to assess clients for depression
and other psychiatric syndromes that are known to affect health
outcomes. A comprehensive process of assessment may be espe-
cially pertinent in those with complex syndromal conditions, such
as menopausal symptom clusters.
Psychotherapy could beneﬁt women  who require medical
support during the climacteric if depressed affect compounds
menopausal symptoms in the manner described. Applied relax-
ation, for instance, has been shown to reduce the frequency of
vasomotor symptoms [39] and the beneﬁcial effects of this and
other psychotherapeutic interventions may be especially pro-
nounced in groups of women  for whom depressed affect is a feature
of the climacteric.
The mediation models were constructed based on a postulated
mechanism and it remains unclear whether the models were
correctly speciﬁed. In addition, epiphenomenal associations may
compromise these ﬁndings despite the models’ inclusion of covari-
ates [28]. This is especially likely given the use of menopausal
status as a proxy for complex biological and psychosocial pro-
cesses, and the study’s reliance on questionnaire measures which
provide raw scores rather than the measurements essential for
parametric statistical analysis [40]. For example, the CES-D with a
cut-off point of ≥16 or higher may  not indicate a clinical diagnosis
ates at paths a and c′ .
Somatic symptoms (Y)
p B SE 95% CI p
0.01 c′ 0.005 0.03 −0.06 to 0.07 0.87
b 0.08 0.01 0.06 to 0.10 <0.001
0.22 0.001 0.02 0.91
<0.001 −0.02 0.01 0.03
0.02 −0.02 0.09 0.65
<0.001 0.27 0.14 0.05
R2 = 0.255
F(5, 198) = 13.59, p < 0.001
ntervals.
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[40] Tennant A, McKenna SP, Hagell P. Application of Rasch analysis in the develop-10 E. Borkoles et al. / Ma
f depressive disorder. Depressive symptoms are also time limited.
urther studies are warranted to conﬁrm our ﬁndings with regards
o risk of depressive symptoms associated with this important
hase of women’s lives.
Future investigation may  consider implementing prospec-
ive designs and substantially larger sample sizes to elucidate
he relationship, causal or otherwise, between depressed affect
enopausal symptoms.
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